secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001628280-26-010740
Event type: other_material
Sentiment:  positive
Materiality: 0.95
Item codes: 1.01, 2.02, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Vir Biotechnology enters global strategic collaboration with Astellas for VIR-5500 prostate cancer T-cell engager
--------------------------------------------------------------------------------

- Vir Bio will receive $335 million in upfront and near-term payments, including $240M cash and $75M equity at 50% premium.
- Eligible for up to $1.37 billion in development, regulatory and sales milestones plus tiered double-digit royalties on ex-U.S. net sales.
- Global development costs shared 40% Vir Bio / 60% Astellas; U.S. profits/losses split 50/50 with Vir co-promotion option.
- Phase 1 data for VIR-5500 shows dose-dependent anti-tumor activity; oral presentation at ASCO GU 2026 on February 26.
- Cash and investments $781.6M as of Dec 31, 2025; net loss for full year 2025 was $438.0 million.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000162828026010740/0001628280-26-010740-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000162828026010740/vir-20260219.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-010740

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer